Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $3.00 USD
Change Today -0.91 / -23.27%
Volume 138.3K
APHB On Other Exchanges
As of 8:04 PM 10/2/15 All times are local (Market data is delayed by at least 15 minutes).

ampliphi biosciences corp (APHB) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/27/15 - $16.75
52 Week Low
10/2/15 - $2.75
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

ampliphi biosciences corp (APHB) Related Businessweek News

No Related Businessweek News Found

ampliphi biosciences corp (APHB) Details

AmpliPhi Biosciences Corporation, a biotechnology company, focuses on the discovery, development, and commercialization of various bacteriophage therapeutics. The company’s lead programs include AmpliPhage-001 for the treatment of cystic fibrosis patients with P. aeruginosa lung infections; AmpliPhage-002 for the treatment of methicillin-resistant S. aureus infections; and AmpliPhage-004 for the treatment of C. difficile infections. It has a collaboration agreement with Intrexon Corporation to utilize synthetic biology platform for the identification, development, and production of bacteriophage-containing human therapeutics. The company was formerly known as Targeted Genetics Corporation and changed its name to AmpliPhi Biosciences Corporation in February 2011. AmpliPhi Biosciences Corporation was founded in 1989 and is headquartered in Glen Allen, Virginia.

18 Employees
Last Reported Date: 05/12/15
Founded in 1989

ampliphi biosciences corp (APHB) Top Compensated Officers

Interim Chief Financial Officer
Total Annual Compensation: $127.1K
Interim Chief Operating Officer and Director
Total Annual Compensation: $60.0K
Compensation as of Fiscal Year 2014.

ampliphi biosciences corp (APHB) Key Developments

AmpliPhi Biosciences Corporation Announces Data Demonstrating Efficacy of a Novel Bacteriophage Cocktail is Comparable to Vancomycin in S. aureus Lung Infection Model

AmpliPhi Biosciences Corporation announced experimental results highlighting that its prototype bacteriophage cocktail demonstrated comparable efficacy to vancomycin in reduction of Staphylococcus aureus (S. aureus) in a murine lung infection model. Data from this study, performed in collaboration with the Hearts Consulting Group and the University of North Texas (UNT) Health Science Center, were presented at the joint Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC) and International Congress of Chemotherapy and Infection (ICC) 2015 meeting, taking place in San Diego from September 17-21. To assess the in vivo efficacy of bacteriophages to treat lung infections, neutropenic immunocompromised (ICR) mice were inoculated intranasally with S. aureus. At two hours post infection, scaled dosing of the bacteriophage cocktail was administered intranasally to three dosage groups (50 µl; n=5 for each group), with a second identical dose administered at six hours post infection. Vancomycin was administered subcutaneously at two and six hours post infection to a fourth, positive control group. Two control groups were infected, but untreated. The groups treated with the bacteriophage cocktail at the two high doses (1 x 109 and 1 x 108 PFU per phage per dose) showed a 3-log reduction in bacterial cell counts relative to untreated controls at the same time point, which was comparable to the efficacy seen in the positive control group treated with vancomycin.

AmpliPhi Biosciences Appoints Alexander Gaidamaka as Vice President of Chemistry, Manufacturing and Control

AmpliPhi Biosciences Corporation announced that Alexander Gaidamaka, Ph.D., D.V.M, has been appointed as the new Vice President of Chemistry, Manufacturing and Control. Prior to his role at AmpliPhi, Alexander served as CEO and CSO of Personalized OncoTherapeutics Inc. He has held executive R&D, product development and quality control roles at Pharma Green LLD, Merial, Sanofi Pasteur, Bioniche Life Sciences Inc. and Biopharm JSC. Dr. Gaidamaka was also previously head of the Department of Immunopharmacology & Allergology at the All-Union Research Institute of Drug Chemistry and Technology, Ukraine.

AmpliPhi Biosciences Corporation Reports Earnings Results for the Second Quarter Ended June 30, 2015; Provides Financial Guidance for the Third Quarter of 2016

AmpliPhi Biosciences Corporation reported earnings results for the second quarter ended June 30, 2015. For the quarter, the company reported loss from operations was $2.6 million compared to $3.7 million in the same period of 2014. Net income was $10.8 million compared to $13.9 million in the same period of 2014. Cash and cash equivalents as of June 30, 2015 totaled $14.4 million, reflecting the net proceeds of $12.4 million from March 2015 private placement financing. The Company anticipates its current financial resources will provide sufficient cash to fund operations through third quarter of 2016.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
APHB:US $3.00 USD -0.91

APHB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for APHB.
View Industry Companies

Industry Analysis


Industry Average

Valuation APHB Industry Range
Price/Earnings 1.2x
Price/Sales 41.7x
Price/Book 1.3x
Price/Cash Flow 1.0x
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AMPLIPHI BIOSCIENCES CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at